Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

• Journal List
• Data Brief
• v.9; 2016 Dec
• PMC5021787

Data Brief. 2016 Dec; 9: 199–205.

Published online 2016 Aug 29. doi:  10.1016/j.dib.2016.08.039

PMCID: PMC5021787

Veit J. Erpenbeck,a,⁎ Todor A. Popov,b David Miller,c Steven F. Weinstein,d Sheldon Spector,e Baldur Magnusson,aWande Osuntokun,f Paul Goldsmith,f Markus Weiss,a and Jutta Beierg

Author information ► Article notes ► Copyright and License information ►

Abstract

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients.

Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1].

Formats:

• Article
 | 
• PubReader
 | 
• ePub (beta)
 | 
• PDF (160K)
 | 
• Citation

Go to:

Abstract

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1]